Hardie I R, Strong R W, Hartley L C, Woodruff P W, Clunie G J
Surgery. 1980 Feb;87(2):177-83.
Between September, 1969, and December, 1978, 290 patients received 325 cadaveric renal allografts; 11 others transplanted elsewhere were also observed. Cancers developed in 28 patients (9.3%); 26 of these (93%) had skin cancers. The incidence of skin cancer increased by 5% annually after the first year of graft function, to a cumulative 44% in those surviving 9 years with functioning grafts. This represents an incidence of 4,356/100,000 person years of post-transplant risk--20.6 times the annual incidence of skin cancer in the general population of Southern Queensland. Half of the patients had multiple tumors when the first skin cancer was diagnosed, after a mean latent interval of 34 months. A total of 138 skin cancers occurred in 26 patients (average, 5.3 per patient), with a maximum of 19 in one individual. The ratio of basal to squamous cell carcinoma was reversed from 4:1, in the general population, to 1:1.7. Conventional surgical excision gave satisfactory results, with the one local recurrence being controlled by reexcision. Two patients (7%) died of melanoma and metastatic squamous cell carcinoma, respectively, whereas two of the other four patients who died from cancer had coincidental skin cancer. The two skin cancer deaths represent only 2% of all deaths in allograft recipients. These results suggest that the problem of skin cancer in these patients can be controlled and thus is not a significant contraindication to the continued clinical use of cadaveric renal transplantation.
1969年9月至1978年12月期间,290例患者接受了325次尸体肾移植;还观察了另外11例在其他地方接受移植的患者。28例患者(9.3%)发生了癌症;其中26例(93%)患有皮肤癌。移植功能第一年之后,皮肤癌的发病率每年增加5%,在移植功能存活9年的患者中累计发病率为44%。这代表移植后风险的发病率为4356/100000人年——是昆士兰南部普通人群皮肤癌年发病率的20.6倍。当首次诊断出皮肤癌时,一半的患者有多个肿瘤,平均潜伏期为34个月。26例患者共发生138例皮肤癌(平均每人5.3例),其中一人最多发生19例。基底细胞癌与鳞状细胞癌的比例从普通人群中的4:1颠倒为1:1.7。传统手术切除取得了满意的效果,一例局部复发通过再次切除得到控制。两名患者(7%)分别死于黑色素瘤和转移性鳞状细胞癌,而另外四名死于癌症的患者中有两名同时患有皮肤癌。这两例皮肤癌死亡仅占同种异体移植受者所有死亡的2%。这些结果表明,这些患者的皮肤癌问题可以得到控制,因此不是尸体肾移植继续临床应用的重大禁忌证。